Documents

Record sales and profitability in FY 2026, with robust growth across all major geographies.

Record revenue and margin growth driven by U.S. launches, biosimilars, and global expansion.

Record revenue, margin expansion, and robust global growth set the stage for sustained outperformance.

Q1 FY 2026 saw double-digit growth, margin expansion, and strong U.S. launches driving outlook.

FY2025 saw record revenue, margin gains, and robust growth in complex generics and India.

Record EBITDA margins and robust growth driven by U.S. and EMEA, with strong R&D pipeline.

Strong revenue and margin growth, with robust outlook and expanding complex generics pipeline.

Double-digit revenue and margin growth driven by new launches and operational excellence.